12th_EU-Presentations

HIV Prevention Strategies: How well do they work?
J. van de Wijgert, University of Liverpool, Liverpool, United Kingdom
Estimating HIV epidemic characteristics from a dated transmission network
P. Kalaghatgi, Max Planck Institute for Informatics, Saarbrücken, Germany
HIV-1 transmission chains in a court case: use of clonal sequences to test direction and timing of transmission
A. Abecasis, Instituto de Higiene e Medicina Tropical, Lisbon, Portugal
Preferential suppression of CXCR4-tropic HIV-1 under cART?
J. Bader, Institute for Medical Microbiology, Basel, Switzerland
Prevalence of resistance mutations associated with decreased susceptibility to rilpivirine in antiretroviral naïve patients from Europe
M. Hofstra, University Medical Center Utrecht, Utrecht, The Netherlands
Clinical Perspective
C. Mussini, Policlinico Modena, Modena, Italy
Laboratory Perspective
F. Garcia, Hospital Universitario San Cecilio, Granada, Spain
Update on new anti-HCV drugs
M. Nelson, Chelsea and Westminster Hospital, London, United Kingdom
Reliability and clinical relevance of HCV sequencing on clinical samples with different HCV-RNA levels
V. Di Maio, University of Rome Tor Vergata, Rome, Italy
HCV genetic background and early detection of resistance mutations are associated with low viral decay and viral failure to first generation protease inhibitors in difficult-to-treat patients
V. Cento, University of Rome Tor Vergata, Rome, Italy
Clinical Case presentation -- HCV
M. Aragri, University of Rome Tor Vergata, Rome, Italy
Basics of Integrase Inhibitors
F. Clavel, Hôpital Bichat-Claude Bernard, Paris, France
Resistance profiles of Integrase Inhibitors
F. Ceccherini-Silberstein, University of Rome Tor Vergata, Rome, Italy
Clinical Case presentations
J. Schapiro, Sheba Medical Center, Ramat Gan, Israel
Challenges in Sub-Saharan Africa
A. Wensing, Eijkman-Winkler Inst, Utrecht, The Netherlands
Increasing prevalence of protease inhibitor resistance mutations in South African adults failing a boosted PI-based regimen
K. Steegen, University of Witwatersrand, Johannesburg, South Africa
Follow-up on cost saving strategies in Catalonia
B. Clotet, H. Univ. Germans Trias i Pujol, Badalona, Spain
HIV Eradication Trials; What are the current Strategies
D. Hazuda, Merck Research Labs, West Point, USA
The role of compartimentalization: Do the current drugs reach all target sites
D. Burger, RadboudUMC, Nijmegen, The Netherlands
One year of routine HIV-1 drug resistance testing by deep sequencing: insights from comparative Sanger sequencing
A. Thielen, Institute of Immunology and Genetics, Kaiserslautern, Germany
Reliability of HIV-1 Integrase genotyping in patients with low viremia levels
M. Santoro, University of Rome Tor Vergata, Rome, Italy
Durable efficacy and limited Integrase resistance in subjects receiving Dolutegravir after failing a prior INI regimen: Week 48 results from VIKING-3
C. Vavro, GlaxoSmithKline USA, Research Triangle Park, USA
Clinical consequences of Raltegravir failure in Spain
J. Santos, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Longitudinal resistance analyses of the phase 3 EVG/COBI/FTC/TDF studies
K. White, Gilead, Foster City, USA
Clinical Case presentation -- HIV
M. Tsakiroglou, University of Liverpool, Liverpool, United Kingdom
Generic antiretrovirals: will they change our clinical practice?
R. Camacho, Hospital Egas Moniz, Lissabon, Portugal
The role of generic antiretrovirals in the scale up of the treatment of HIV infection
J. Lange, AIGHD, Amsterdam, The Netherlands